Deutsches Ärzteblatt international
December 16, 2024
Moritz Spangemacher, Andrea Jungaberle, Henrik Jungaberle et al.
3 citations
Treatment with psilocybin differs fundamentally from classic psychopharmacotherapy. Its potentially transdiagnostic, rapid, and sustainable efficacy and its positive effect on further dimensions of mental health beyond the patient's symptoms and psychopathology imply that it may have diseasemodifying and salutogenic mechanisms of action. Psychotherapy accompanied by the administration of...
bioRxiv Preprint Server
December 12, 2024
Lauri Elsilä, Elina Nagaeva, Jari-Pekka Luukkonen et al.
1 citation
preprint
The current research on psychedelic compounds such as lysergic amide diethylamide (LSD) is leaning heavily on the notion that psychedelics are not addictive. While much of the literature supports this argument, some of the common use patterns and the descriptions of the subjective effects of these compounds in humans, together with rather lacking and mixed data from non-human animal studies...
Revista Ibero-Americana de Humanidades, Ciências e Educação
December 4, 2024
Tamyres Cordeiro Leoncio, Danilo Cândido de Araújo Batista
O LSD (dietilamida do ácido lisérgico), tradicionalmente conhecido por seus efeitos psicodélicos, tem atraído crescente interesse na pesquisa científica devido ao seu potencial terapêutico em uma série de distúrbios neurológicos e psiquiátricos. Este artigo revisa as evidências recentes sobre os efeitos do LSD, destacando sua capacidade de promover a neuroplasticidade, modular o sistema...
Drug Testing and Analysis
December 3, 2024
Simon D. Brandt, Pierce V. Kavanagh, Sarah Gare et al.
5 citations
The classical psychedelic drug (+)-lysergic acid diethylamide (LSD) continues to attract considerable multidisciplinary interest, and over the last eight decades, many derivatives and analogs of LSD have been synthesized. One site on the ergoline scaffold of LSD that has been frequently modified is the N1-position, with the N1-acylated LSD derivative 1-acetyl-LSD (1A-LSD, ALD-52) being one of...
Acta Psychiatrica Scandinavica
December 3, 2024
Vikas Menon, Parthasarathy Ramamurthy, Sandesh Venu et al.
15 citations
ABSTRACT Introduction There is growing interest in the use of psychedelic‐assisted therapy (PAT) for major depressive disorder (MDD), including treatment‐resistant depression. We used randomized controlled trial (RCT) data to compare summary estimates of change in depression ratings with PAT versus comparator treatments in MDD. We also compared response and remission rates, and adverse effects....
Veterinary research communications
December 1, 2024
Luis Alberto Henríquez-Hernández, Ignacio García-Serrano, Domingo J Quintana-Hernández et al.
4 citations
Anxiety affects 14-20% of dogs. Pharmacological treatments often fail. Psychedelics have shown to be useful for anxiety and depression in humans, but their veterinary use remains unexplored. We aimed to determine the effects of low-dose 1-cyclopropionyl-d-lysergic acid diethylamide (1cp-LSD) administered in a single dose to a dog, to observe the effect and establish the safety of the substance....
Asian Journal of Psychiatry
December 1, 2024
Hitesh Kumar Behera, Ramesh Joga, Sravani Yerram et al.
Psychedelic drug therapy has gained prominence for its potential in treating various mental health conditions, including depression, post-traumatic stress disorder (PTSD), and anxiety. Psychedelic treatment differs from conventional psychiatric approaches in mode of action, legal status, and treatment approach. This work delves into the therapeutic potential, mechanisms, and regulatory...
Current Psychiatry Reports
December 1, 2024
Daan de Jonge, Pim B. van der Meer, Cornelis Kramers et al.
2 citations
In this narrative review, we discuss evidence for psilocybin- and LSD-assisted treatment of alcohol use disorder (AUD) and major depressive disorder (MDD). We describe limitations of psychedelic research and posit methodological considerations when designing a trial in patients with both disorders. In AUD, a growing evidence base for psilocybin treatment shows a promising beneficial and...
Psychedelic Medicine
December 1, 2024
Connor J Haggarty, Hanna Molla, James Glazer et al.
2 citations
Despite widespread popular interest in the use of low doses of Lysergic acid diethylamide (LSD) to improve mood, little is known about how these doses affect emotional processing in the brain. In this study, we tested the effect of a single low dose of LSD (26 µg) compared with placebo on electroencephalogram (EEG) event-related potentials (ERP: N170, P300 and Mismatch Negativity) in healthy...
Harm Reduction Journal
November 5, 2024
Chris Wilkins, Jose Romeo, Marta Rychert et al.
8 citations
The substitution of cannabis for alcohol and other drugs has been conceptualised in a harm reduction framework as where cannabis is used to reduce the negative side-effects, addiction potential, and social stigma of other drugs. There is currently mixed evidence with recent reviews suggesting cannabis co-use patterns may vary by age and ethnicity. Yet few studies have had large enough samples...
Pharmaceuticals
November 5, 2024
Tamara Valdez, Valbhi Patel, Nattaphone Senesombath et al.
4 citations
Psychedelics have recently (re)emerged as therapeutics of high potential for multiple mental health conditions, including substance use disorders (SUDs). Despite early mid-20th century anecdotal reports and pilot studies demonstrating the possibility of these substances in efficaciously treating conditions such as alcohol and opioid use disorders, legal restrictions and social stigma have...
Advanced Science
November 1, 2024
Wei Ren, Shan Yu, Kun Guo et al.
14 citations
Dogs interact with humans effectively and intimately. However, the neural underpinnings for such interspecies social communication are not understood. It is known that interbrain activity coupling, i.e., the synchronization of neural activity between individuals, represents the neural basis of social interactions. Here, previously unknown cross-species interbrain activity coupling in...
International Journal of Drug Policy
November 1, 2024
Rodolfo Olivieri, Luís Fernando Tófoli
1 citation
This essay examines the combination of psychoanalytic therapy and psychedelic substances in mid-20th century Argentina. Through document analysis, it examines the intersection of psychedelics and psychoanalysis, drawing from historical texts and writings by local psychoanalysts to develop a comprehensive understanding of the distinctive clinical practices and therapeutic approaches in the...
Current Topics in Behavioral Neurosciences
October 23, 2024
Grace Viljoen, Felix Betzler
5 citations
There is a large and rapidly growing body of literature investigating the therapeutic effects of classic psychedelics in affective and anxiety disorders, but very few studies have examined the inverse of this, that is, the potential for psychedelics to inflict anxiety and affective symptoms. A systematic literature search was performed and 39 papers were included in the final review to...
Revista Eletrônica Acervo Saúde
October 18, 2024
Lucas Siqueira Dos Santos, João Marcos Santos Oliveira, Layane Estefany Siqueira Dos Santos
Objetivo: Analisar as consequências para a saúde mental provocadas pelo consumo do Dietilamida do Ácido Lisérgico (LSD) e metilenodioximetanfetamina (MDMA) por jovens e adolescentes. Revisão bibliográfica: Este artigo promove uma discussão e análise acerca do consumo desenfreado de LSD e MDMA por jovens e adolescentes. O crescimento exponencial do mercado ilegal do tráfico de drogas e a criação...
Neuron
October 9, 2024
Luyu Fan, Youwen Zhuang, Hongyu Wu et al.
6 citations
Understanding the kinetics of LSD in receptors and subsequent induced signaling is crucial for comprehending both the psychoactive and therapeutic effects of LSD. Despite extensive research on LSD's interactions with serotonin 2A and 2B receptors, its behavior on other targets, including dopamine receptors, has remained elusive. Here, we present cryo-EM structures of LSD/PF6142-bound dopamine...
British Journal of Pharmacology
October 2, 2024
Ryan H. Gumpper, David E Nichols
9 citations
This brief review highlights some of the structure-activity relationships of classic serotonergic psychedelics. In particular, we discuss structural features of three chemotypes: phenethylamines, ergolines and certain tryptamines, which possess psychedelic activity in humans. Where they are known, we point out the underlying molecular mechanisms utilized by each of the three chemotypes of...
European Addiction Research
September 25, 2024
Ioanna A. Vamvakopoulou, David Nutt
13 citations
Background: Psychedelic substance use in ritualistic and ceremonial settings dates back as early as 8,500 BCE. Only in recent years, from the mid-20th century, we have seen the re-emergence of psychedelics in a therapeutic setting and more specifically for the treatment of addiction. This article aims to review research over the past 40 years using classic (psilocybin, lysergic acid...
Cortica
September 21, 2024
Maya Oberson
Dans ce travail, l’objectif principal est d’explorer les effets et l’efficacité du diéthylamide de l'acide lysergique, plus communément connu sous le nom de LSD, dans le traitement du trouble lié à l’usage de l’alcool. Une recherche systématique, s’appuyant sur différentes bases de données, a été menée dans le but de sélectionner des articles traitant de la problématique en...
Journal of Psychopharmacology
September 20, 2024
Abigail E. Calder, Benjamin Rausch, Matthias E. Liechti et al.
17 citations
Background: Psychedelic-assisted therapy (PAT) is permitted in Switzerland under its limited medical use program. Data from patients in this program represent a unique opportunity to analyze the real-world practice of PAT. Aims: This study compared the subjective effects of lysergic acid diethylamide (LSD) and psilocybin between patients undergoing PAT and healthy volunteers. For the patients,...